Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.

New physician research identifies opportunities for differentiated Hidradenitis Suppurativa therapies as biologic prescribing ...

Candidates Cosentyx and bimekizumab are possible contenders with Phase III trials underway Remicade, which is not approved, might be the real success bar in this chronic skin disease. It is ...

Trickett and Neita compare adalimumab, secukinumab, and bimekizumab trial data and explain how comorbidities guide biologic ...

Adalimumab use among patients with HS was associated with a greater risk of developing psoriasis and psoriatic arthritis through 1 year.

Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with ...

In just the last quarter, the number of HS patients treated with biologics has increased 27% year over year. According to Spherix, that increase likely represents not only biologics’ grabbing market ...

People taking adalimumab (Humira) for moderate-to-severe hidradenitis suppurativa (HS) saw better results across the board when the drug was combined with a surgical intervention. That's according to ...

Patients with HS on adalimumab have a 53% higher risk of serious infections than those with psoriasis. HS patients are more prone to sepsis and genitourinary infections, with longer hospital stays.

Among adults treated with adalimumab, those with hidradenitis suppurativa (HS) showed a 53% higher risk for serious infections than adults with psoriasis, with notably increased risks for sepsis and ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa, post hoc analysis of the PIONEER I and II ...